HR Execs on the Move

CymaBay

www.cymabay.com

 
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cymabay.com
  • 7999 Gateway Blvd. Suite 130
    Newark, CA USA 94560
  • Phone: 510.293.8800

Executives

Name Title Contact Details

Similar Companies

BioMotiv

BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.

Oncothyreon

Oncothyreon is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.

Blaze Bioscience

Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided therapies. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children`s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide*-based guided therapeutics.

Regenacy Pharmaceuticals

Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.